Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation.
BACKGROUND
The aim of this study was to investigate the association of donor CD4(+) T cells expressing CD62L with transplant outcomes.


METHODS
We report a prospective analysis of 31 patients who were treated with a Bu/Cy regimen, followed by unmanipulated blood and marrow transplantation.


RESULTS
Median number (range) of CD4(+)CD62L(+), CD4(+)CD45RA(+)CD62L(+), and CD4(+)CD45RO(+)CD62L(+) cells infused were 0.31(0.05-1.10)x10(8)/kg, 0.22(0.03-0.95)x 10(8)/kg, and 0.17(0.01-0.81)x10(8)/kg, respectively. The incidence of grades II to IV aGVHD was 36%. In a multivariate analysis, infusion of >0.22 x 10(8) CD4(+)CD45RA(+)CD62L(+) cells infused/kg increased the risk of grades II to IV aGVHD (HR = 4.741, 95% CI = 1.037-21.662, P = 0.045). Thirteen of 31 patients experienced cGVHD, the risk of cGVHD was increased in patients receiving >0.45 x 10(8) CD4(+)CD45RA(+) cells infused/kg (HR = 4.614, 95% CI = 1.265-16.829, P = 0.021).


CONCLUSIONS
Our results suggest that a high cell dose of CD4(+)CD45RA(+)CD62L(+) cells increase the incidence of grades II-IV aGVHD. A high number of CD4(+)CD45RA(+) cells infused were associated with increased risk of cGVHD in our transplant settings.
Chang
Ying-Jun
YJ
Peking University Institute of Hematology, Peking University People's hospital, Beijing 100044, China.
Zhao
Xiang-Yu
XY
Huo
Ming-Rui
MR
Huang
Xiao-Jun
XJ
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002908:Chronic Disease; D005260:Female; D005786:Gene Expression Regulation; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000276:immunology* / Q000503:physiopathology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D019041:L-Selectin / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology
D019041:L-Selectin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017493:Leukocyte Common Antigens; C516769:PTPRC protein, human